Recurrences of both oral-labial and genital herpes simplex virus (HSV) infections in humans occur frequently. In over 60% of patients with initial genital HSV type 2 (HSV-2) infections, the infection recurs within 6 months, and patients with recurrent genital disease have a median of five recurrences per year (6, 16) .
Both humoral and cellular immune responses are important in controlling experimental and human HSV infections. In mice, virus-specific antibodies prevent the spread of virus from the site of primary infection to the spinal cord (16) and reduce the extent of viral replication in sensory ganglia (22) . Furthermore, antiviral immunoglobulin G prevents the appearance of infectious virus in transplanted latently infected ganglia (21) . The importance of cellular immunity in preventing HSV recurrence is suggested by the increased incidence and severity of herpetic infection among immunosuppressed patients (1, 2, 14, 18) . However, patients with both oral and genital infections experience recurrences de- spite high levels of neutralizing antibodies and virus-specific cellular immunity (7, 12, 17) . To explain this paradox, detailed analyses of the specificities of the immune responses during primary and recurrent infections are needed. This is especially important if recurrences are caused by temporal deficiencies in one or more of the many immune parameters associated with herpesvirus infections.
Recently, we compared sera from patients with recurrent facial infections with those from seropositive individuals without recurrences for antibodies against herpesvirus antigens (26) . However, this study did not evaluate persons with primary HSV infections. We report here findings on 12 patients with initial genital herpes infection who were followed prospectively for a long period of time and from whom a large number of serum samples were obtained soon after the initial infection as well as immediately before and after recurrences of the disease. These samples were used to determine the sequential appearance of antibodies against a number of HSV-2-specific antigens and the persistence of these antibodies as recurrent infections developed.
The Curtiss strain of HSV-2 was obtained from A. Friedman, Merck Institute for Therapeutic Research, West Point, Pa. It was plaque purified three times in primary rabbit kidney cells under carboxymethylcellulose (19) and then grown in primary rabbit kidney cells (for details, see reference 26) .
Clinical isolates were obtained from the vesicular fluid of primary and recurrent genital lesions. Vesicular lesions were opened with a 25-gauge needle; the vesicular fluid was collected and the base was scraped with a calcium alginate swab (Inolex Corp., Glenwood, Ill.), and this was placed in Eagle minimal essential medium (EMEM). Within 4 h of collection, 0.25 ml was inoculated into duplicate tubes of fetal tonsil cells in EMEM plus 1% fetal calf serum (24) . Cultures were examined three times a week for cytopathic effect, and the cells and supernatant fluids from positive cultures were stored at -70°C. Virus was plaque purified twice, and stocks were prepared as described above. Alternatively, stocks were prepared without plaque purification by infecting primary rabbit kidney cells at a multiplicity of infection of 0.01.
Neutralizing antibody determination. Methods have been described for measuring complement-fixing (CF) antibodies to HSV-2 (24), complement-independent neutralizing antibodies (15, 23) , and complement-dependent neutralizing antibodies (26 Tables 1 and   2 .
Acute-phase sera and the initial clinical HSV isolates were obtained from all patients within 11 days of the onset of symptoms or lesions or both (mean, 7.4 days). Eight patients (2, 3, 6, 7, 8, 9, 11 , and 12) did not have CF or neutralizing antibodies in their acute-phase sera (Table 1) , and presumably they experienced a primary infection (15) . The other four patients (1, 4, 5 , and 10) had herpesvirus-specific antibodies in their acute-phase sera. The high antibody levels in patients 4 and 5 clearly suggest previous exposure to HSV. Acute-phase sera from patients 1 and 10 were obtained relatively late after the onset of initial lesions (11 days) compared to the other patients, and they lacked complementindependent HSV-2-neutralizing antibodies (patient 10) or CF antibodies (patient 1). Thus, the nature of the infection (primary or secondary) could not be established with certainty for these patients. Immunoprecipitation analyses (see below) did suggest that patient 1 had a primary infection and that patient 10 had been exposed to HSV at an earlier date. CF and complement-enhanced HSV-2-neutralizing antibodies were present in all early convalescent-phase serum samples except that from patient 6. Late convalescent-phase serum samples, except that from patient 6, contained complement-dependent and complement-independent HSV-2-specific antibodies. Except for patient 7, all eight patients with primary infections, and patient 1, with a possible primary infection, had higher HSV-2-specific than HSV-1-specific complement-independent neutralizing antibody titers. Therefore, these patients were likely to be infected with HSV-2. identified after electrophoresis in sodium dodecyl sulfate-polyacrylamide gels.
The immunoprecipitation patterns ( Fig. 1 ) differed for the various sera, with some precipitating more than 18 viral polypeptides and others being similar to control seronegative serum.
[35S]methionine was added to infected cells late in the replication cycle, when host protein synthesis had ceased, and it is likely that all polypeptides visible on the gels were virus coded. Furthermore, polypeptides were not precipitated by immune serum from radiolabeled extracts of uninfected cells (data not shown), and control serum reacted only slightly with only one polypeptide (see the last track in Fig. 1B) . The largest major precipitated polypeptide (labeled C in Fig. 1 ) is the major constituent of viral nucleocapsids (4, 20) . Next there is a group of at least two polypeptides that are glycoproteins (labeled GP130 in Fig. 1 ) with an approximate molecular weight of 130,000 (4). They are referred to here as GP130. The nature of the other polypeptides, including a major precipitated polypeptide of 62,000 molecular weight (P62), was not determined.
Virus-specific antibodies during initial genital herpes infections. Acute-phase sera of five of the seven patients without significant CF or neutralizing antibody titers (patients 2, 3, 6, 8, and 9) demonstrated immunoprecipitation patterns similar to that of the seronegative control; there was no reaction or a weak reaction with the glycoprotein and no reaction with the nucleocapsid polypeptide (Fig. 1) . Acute-phase sera from the two other patients with primary infections (patients 7 and 12) reacted only with the GP130 complex. Two acute-phase serum samples were taken from patient 11. The first one, which lacked CF antibody and complementindependent neutralizing antibodies, was not available for immunoprecipitation analyses. Another sample taken 5 days later, which had measurable CF and neutralizing antibodies, precipitated a number of viral antigens, including GP130, the nucleocapsid, and P62 antigens.
Acute-phase serum from patient 4, with evidence of prior HSV infection, contained a wide range of antibodies to viral polypeptides, whereas that from another patient with a nonprimary initial infection (patient 5) reacted with the nucleocapsid polypeptide and GP130, but only weakly with other HSV-2 antigens.
Virus-specific antibodies in convalescent-phase sera. All late convalescent-phase sera (labeled L in Fig. 1 immunoprecipitation patterns that were intermediate between those of acute-phase and late convalescent-phase sera. Interestingly, serum from patient 6 that failed to neutralize HSV-2 (Curtiss) did react with the nucleocapsid polypeptide, GP130, and P62 that were synthesized by this HSV-2 strain.
Measurements of CF and neutralizing antibodies in the sera of patients 1 and 10 could not establish whether infections were primary or secondary (see above). The immunoprecipitation patterns (Fig. 1) Sequential development of virus-specific antibodies after infection. The results (Fig. 1 ) also show that antibodies against the various HSV antigens developed in a specific sequence. This is most readily observed when one compares the acute-phase and early and late convalescentphase sera from patients 2, 6, 7, 8, and 9. Antibodies to the GP130 complex developed first, followed by antibodies against the major nucleocapsid polypeptide. These in turn were followed by antibodies against a variable number of other viral antigens, in particular, polypeptide P62.
Relationship between recurrence rates and presence of virus-specific antibodies. An attempt was made to correlate the presence or absence of certain virus-specific antibodies with the severity of the initial infection and the incidence of recurrent infections. As discussed above, convalescent-phase sera of all patients had antibodies against the major nucleocapsid polypeptide, GP130, and P62. The presence of other antibodies, in particular those against polypeptides with molecular weights between 30,000 and 43,000, was more variable.
When the nine patients with primary genital HSV-2 infections (including patient 1) were evaluated as a separate group, a trend (although not statistically significant) was observed. Patients 2, 3, 6, and 9, whose sera were weakly reactive with the 30,000-to 43,000-molecular-weight polypeptides, had a mean duration of viral shedding and lesions of 8. current episodes. (The gel was overexposed to make minor precipitated polypeptides visible.)
It should be noted that the immunoprecipitation pattern in Fig. 2 (with primary rabbit kidney cells) differed from that for patient 12 in Fig. 1 (with mouse embryo fibroblasts). When the sera from the other 12 patients were reacted with primary rabbit kidney cell extracts, the same differences among patients were observed as shown in Fig. 1; i.e., convalescent-phase sera from patients 2, 3, 6, and 9 precipitated far fewer HSV-2-specific antigens than did the sera from the other patients.
Immunoprecipitation assays similar to those shown in Fig. 1 and 2 were also carried out with extracts of cells infected with the viral isolates from an initial and a recurrent lesion of patient 12 and an initial lesion of patient 10. No significant differences were observed between the immunoprecipitation patterns of these clinical isolates and the HSV-2 (Curtiss) strain.
Quantitation of antibodies against the GP130 complex in patient sera. The immune response to the GP130 glycoprotein complex was quantitated with material from HSV-2 (Curtiss)-infected primary rabbit kidney cells that specifically bound to the lectin from L. culinaris. It has been found that more than 85% of the bound radiolabeled virus-specific polypeptides consist of the GP130 complex (25) .
To Fig. 3 show that there was little difference between the early convalescent-phase and subsequent serum samples in antibody titers to the GP130 complex. Specifically, transient decreases in antibodies to the GP130 complex were not detected in specimens taken shortly before recurrences. In fact, there was a trend toward increased reactivity in samples taken late in the course of the disease. This could represent hyperimmunization of this individual because of repeated exposure to the virus during recurrent episodes of disease. Similar results were obtained with sequential serum samples from the other patients. Glycoprotein fractions were also prepared from primary rabbit kidney cells infected with clinical isolates from patients 10 and 12, and they were used for titration experiments. Results similar to those in Fig. 3 were obtained (data not shown).
DISCUSSION
Studies of antibody responses to virus-specific polypeptides in patients with initial genital HSV infections were undertaken in patients who presented early in the course of infection and who were prospectively followed with frequent virus isolations, periodic serum samplings, and regular clinical observation. Radioimmunoprecipitation assays were used to determine the sequential development of HSV-2-specific antibodies during initial genital herpes infections and to evaluate whether antibodies persisted immediately before, during, and after recurrent episodes.
Our data indicate a sequential evolution in the antibody response to virus-coded polypeptides during primary genital herpes. Antibodies against a high-molecular-weight (130,000) glycoprotein complex appeared first, followed by antibodies against the major 150,000-molecularweight nucleocapsid polypeptide. Next antibodies appeared against a number of other viral antigens. Among the latter was a polypeptide with a molecular weight of 62,000. This does not appear to be a surface glycoprotein (no incorporation of [3H]glucosamine, no binding to lectin from L. culinaris, and no iodination in the presence of lactoperoxidase; data not shown), and therefore it is not one of the major type-common viral envelope glycoproteins (5, 8) . All patients with serological evidence of prior HSV-1 or HSV-2 infection had antibodies reactive with both the GP130 and nucleoprotein antigen in serum drawn early in the initial genital infection.
Because Fig. 2 , except that the acutephase serum sample taken on 5/4n6 was used, and the late-phase sample taken on 7/30/6 was omitted.
with those against the nucleocapsid and core antigens without being detected at that time. It was of interest that patient 6, without neutralizing antibodies against HSV-2 (Curtiss), did demonstrate reactivity with HSV-2 (Curtiss)-specific polypeptides in his convalescent-phase serum. This case illustrates the apparent utility and increased sensitivity of these immune precipitation reactions compared to standard serological tests as a measure of immunological responsiveness to HSV-2.
The data suggest but do not prove an association between the immune response to virusspecific polypeptides during initial genital infections and the severity of the initial infection, as well as the subsequent recurrence rate of disease. Only nine patients with primary genital infections were studied. Among them, six (patients 1, 3, 7, 8, 11, and 12) experienced frequent recurrences, with a mean recurrence rate of 2.03 per 100 patient days of follow-up, and three (patients 2, 6, and 9) experienced either no VOL. 37, 1982 on October 27, 2017 by guest http://iai.asm.org/ Downloaded from recurrence or infrequent recurrence, with a mean recurrence rate of 0.14 per 100 patient days offollow-up. The early convalescent-phase sera from the six patients who had frequent recurrences reacted strongly with the nucleocapsid polypeptide, the GP130 complex, and a large number of minor viral antigens, especially those with molecular weights between 30,000 and 43,000 (Fig. 1) . Sera from patients who had infrequent recurrences did not react well with the 30,000-to 43,000-molecular-weight polypeptides. These data suggest that the host immune response to initial genital infection is a determinant of subsequent recrudescent disease. It should be remembered, however, that there is great variability in the clinical course of initial genital HSV infection, and extension of these observations to more patients is needed.
In previous studies of larger cohorts of patients, we have shown that patients with serological evidence of prior HSV-1 infection tend to have a shorter course of initial genital disease than do patients without prior exposure to HSV (6) . To date, follow-up has indicated no difference in subsequent recurrence rates between these two groups of patients (19a; unpublished data). In addition, among patients with primary genital HSV-2 infection, a correlation between high titers of complement-independent neutralizing antibody to HSV-2 titer in early convalescent-phase serum and the subsequent rate of recurrence was observed (Reeves et al., in press). Similarly, in mice a correlation was found between the severity of initial genital infection, the level of neutralizing antibody in convalescent-phase serum, and the ability to demonstrate latent virus in sacral nerve root ganglia (10). Continued prospective evaluation of intensively followed patients with these radioimmunoprecipitation techniques, including attempts to quantitate the amount of virus associated with the initial episode of disease in all the infected anatomical areas, should provide more definitive data concerning the causal relationship between severity of illness, host immune response to initial infection, and rates of recurrence.
Sequential serum samples taken from a number of individuals during the course of follow-up indicated that antibody specificity to the virusspecific polypeptide did not change regardless of whether samples were taken shortly before, during, or after recurrent episodes of disease.
These data agree with an earlier observation (26) that virus-specific antibodies do not fluctuate during recurrent facial herpes infections. Although these data appear to suggest that fluctuations in the levels of antibodies are not a factor in recrudescent disease, it should be remembered that these immunoprecipitation techniques may not detect all relevant viral antigens. In addition, each antigen contains numerous antigenic sites and their corresponding antibodies. Within these populations there may be changes that correlate with recurrent infections, and the immunoprecipitation assays used would not detect these changes. Monoclonal antibodies directed against specific regions of relevant antigens should allow for a more accurate evaluation of the possible role of transient fluctuations of specific antibody levels in recurrent infections. Further development of these reagents should also allow the quantitation of antibody responses to virus-specific antigens other than the GP130 complex, especially those antigens with molecular weights between 30,000 and 43,000. 
ADDENDUM IN PROOF
The type specificity of the viral isolated from the 12 patients was confirmed by the indirect immunoperoxidase method (D. Benjamin, Appl. Microbiol. 28:568-571, 1974). HSV isolated from patient 6 was type 1, the other isolated were type 2.
